JPS6156114A - Cosmetic for preventing skin aging - Google Patents
Cosmetic for preventing skin agingInfo
- Publication number
- JPS6156114A JPS6156114A JP59178971A JP17897184A JPS6156114A JP S6156114 A JPS6156114 A JP S6156114A JP 59178971 A JP59178971 A JP 59178971A JP 17897184 A JP17897184 A JP 17897184A JP S6156114 A JPS6156114 A JP S6156114A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- effect
- octan
- cosmetic
- bicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は皮膚老化防止用化粧料(皮膚の老化防止に用い
る皮膚化粧料に閃する。更に詳しくは皮膚老化防止効果
(荒れ肌改善効果、角+1:1改會効果、皮膚まTこは
角質層のターンオーバー速度を速くする効果、しわの減
少等)の侵れ1こ皮膚化粧料に関する。Detailed Description of the Invention (Industrial Application Field) The present invention relates to cosmetics for preventing skin aging (skin cosmetics used for preventing skin aging). +1:1 reforming effect, effect of increasing the turnover rate of the stratum corneum, reduction of wrinkles, etc.).
(従来の技術) 。(Conventional technology)
老化皮膚とは、乾燥して滑らかのf、Cい荒れ肌で、角
質細胞の剥離現象が認めら01、結合相識はコラーゲン
/エラスチン比が高く、しわが多い。そして老化皮膚は
細胞代謝の低下によりターンオーバー速度が遅く、従っ
て皮膚に老化防止効果が付与発現するとターンオーバー
速度が速くなると言われている。特表昭59−5007
70号公報には、特定の脂環式化合物がコラーゲンの生
成を減少させ、エラスチンの生成を促進するこみにより
皮jaのしわを減少させる作用があることが記述されて
いる。Aging skin is dry, smooth, rough, and rough skin with peeling of corneocytes, a high collagen/elastin ratio, and many wrinkles in the connective phase. It is said that aging skin has a slow turnover rate due to a decrease in cell metabolism, and therefore, when an anti-aging effect is imparted to the skin, the turnover rate becomes faster. Special edition 1986-5007
Publication No. 70 describes that certain alicyclic compounds have the effect of reducing wrinkles in the skin by reducing the production of collagen and promoting the production of elastin.
しかしながら、前記特定の脂環式化合物単独では、エラ
スチン形成促進作用があるのみで番往捉1瑯1オ填墳東
1瀉囁瑯埋1ツ9=、皮ml老化に対して満足すべき効
果を得ることは困難であり、かつその効果も一過性であ
る。However, the specific alicyclic compound alone only has an effect of promoting elastin formation, and has a satisfactory effect on skin aging. It is difficult to obtain, and the effect is temporary.
一万、特公昭58−26726号公報には、アミン醋酸
系化合物が皮膚の末梢血管拡張作用により皮膚機能を冗
進し、老化防止効果を有することが開示さ口ている。10,000, Japanese Patent Publication No. 58-26726 discloses that amine acetic acid compounds enhance skin functions by dilating the skin's peripheral blood vessels and have an anti-aging effect.
しかしながら、γ−アミノ酪酸系化合物単独では、皮膚
老化防止効果は遅効性で、クリームの場合は6ケ月後、
ローションの場合は3ケ月後にならないと効果は現わ口
、ず、また結合組織のコラーゲン/エラスチン比を低く
して皮膚のしわtg少させる作用はない。However, with γ-aminobutyric acid compounds alone, the anti-aging effect on the skin is slow-acting, and in the case of creams, after 6 months,
In the case of lotions, the effects do not appear until three months later, and they do not have the effect of lowering the collagen/elastin ratio of connective tissue to reduce wrinkles in the skin.
(発明が解決しようとする問題点)
本発明者等は、前記従来技術の欠点を改良せんとして、
鋭意研究し1こ結果、皮膚化粧料の基剤の中に、後記特
定の脂環式化合物と、後記特定の物簀ヒl第1↑1を嘲
i垢者の両者を併用する場合は、両者による相乗効果に
よって優rL1こ皮ハ輸′老化防止効果(荒れ肌改善効
果、角質改善効果に優れ、結合組織のコラーゲン/エラ
スチン比を低くしてしわを少なくシ、ターンオーバー速
度ケ速くする効果)が使用開始後1ケ月というごく短時
間に発現する速効性で、かつ持続性のある皮膚老化防止
用化粧料が得らnることを見出し、本発明を完成し1こ
。(Problems to be Solved by the Invention) The present inventors, in an attempt to improve the drawbacks of the prior art,
After extensive research, we found that when both the specific alicyclic compound listed below and the specific compound listed below are used together in the base of skin cosmetics, The synergistic effect of both of them results in excellent anti-aging effects on the skin (improves rough skin, improves keratin, lowers the collagen/elastin ratio of connective tissue, reduces wrinkles, and speeds up turnover rate). The present invention was completed based on the discovery that it is possible to obtain a cosmetic product for preventing skin aging that is fast-acting and long-lasting, and which develops in a very short period of time, such as one month after the start of use.
(問題点を解決する1こめの手段)
すなわち、本発明は、6−(5−メトキシヘプト−1−
イル)−ビシクロ−[3,3,01オクタン−3−オン
ヶ(以下、脂環式化合物の1という)、6−(5−エト
キシヘプト−1−イル)−ビシクロ−[3,3,03オ
クタン−3−オン0〕オクタン−3−オンf(以下、脂
環式化合物の3という)からなる群から選択さn tニ
ー脂環式化テート、ヒアルロン酸、エラスチン、水溶性
コラあるいは細胞賦活剤という)の少なくとも一つとを
配合してなる皮膚老化防止用化粧料である。(First Means to Solve the Problems) That is, the present invention provides 6-(5-methoxyhept-1-
yl)-bicyclo-[3,3,01 octane-3-one (hereinafter referred to as 1 of the alicyclic compound), 6-(5-ethoxyhept-1-yl)-bicyclo-[3,3,03 octane- 3-one 0] octan-3-one f (hereinafter referred to as alicyclic compound 3); ) is a cosmetic for preventing skin aging.
前記特定の脂環式化合物の配合量は、化粧料組成物の全
殖重世に対して0.0001〜3.0重λ%、好ましく
は0.001−0.5重M%である。配合量が0.01
101重量%米満では、本発明の目的とする効果が充分
でなく、一方3.0重量%を超えてもその増加分に見合
っ1こ効果の向上は望めない。The amount of the specific alicyclic compound blended is 0.0001 to 3.0 weight λ%, preferably 0.001 to 0.5 weight M%, based on the total weight of the cosmetic composition. The blending amount is 0.01
At 101% by weight, the effect aimed at by the present invention is not sufficient, and on the other hand, even if it exceeds 3.0% by weight, no improvement in the effect can be expected in proportion to the increase.
前記特定の血行促進剤あるいは細胞賦活剤のうち、天然
物の抽出物であるセンブリエキス、朝鮮ニンジンエキス
の製造法に関しては特定されるものではないが、各々の
製造法の概要1ユ下記の通りである。Among the above-mentioned specific blood circulation promoters or cell activators, the manufacturing method for the natural product extracts such as Oriental japonica extract and Korean ginseng extract is not specified, but a summary of each manufacturing method is as follows. It is.
センブリ(Swertia Japonica Mak
ino)の開花期全草の乾燥粉砕物をエタノール或いは
含水エタノール中で温浸し、ろ別して得られ1こ抽出液
である。実施例には、下記の方法で得らt″Lに抽出液
を利用しfこ。Swertia Japonica Mak
This is an extract obtained by digesting the dry and pulverized whole plant of P. ino) in the flowering stage in ethanol or aqueous ethanol and filtering it. In the examples, an extract obtained by the method described below was used.
センブリ細砕物50pe含水エタノール(エタノール9
0wt%)250 mlに温度40〜50°Cで温浸し
てろ別し1こ後、再び残渣を同様に温浸することを数回
くり返し、抽出液1.51!を得Tこ。こnを減圧濃縮
し1こ残留物に精製水を100m/ 加え、1週間熟成
した後、不溶部をろ別して得1こ抽出液を減圧濃縮し、
次いでエタノールを加えて抽出液のエタノール含有量が
40wt%になるように調整し、100m1!のセンブ
リエキスを得1こ。50 pe of crushed Aspergillus aqueous ethanol (ethanol 9
0wt%) 250 ml was digested at a temperature of 40 to 50°C, filtered and separated, and the residue was digested in the same manner several times. I got it. This was concentrated under reduced pressure, 100 m/ml of purified water was added to the residue, and after aging for 1 week, the insoluble portion was filtered off, and the extract was concentrated under reduced pressure.
Next, ethanol was added to adjust the ethanol content of the extract to 40 wt%, and the volume was adjusted to 100 ml! Obtain 1 piece of Aspergillus japonica extract.
[朝鮮ニンジンエキスの製造法〕
オタネニンジン(Panax ginseng CA、
Meyer)の5〜6年根乾燥細砕物をエタノール或い
は含水エタノール中に冷浸し、ろ別して得られ1こ抽出
液である。実施例には下記の方法でえられ1こ抽出液を
利用した。[Production method of Korean ginseng extract] Panax ginseng (Panax ginseng CA,
This is an extract obtained by cold soaking a 5- to 6-year-old dried and crushed root of A. Meyer) in ethanol or water-containing ethanol and filtering it. In the examples, an extract obtained by the following method was used.
オタネニンジン細砕物50yを含水エタノール(エタノ
ール90 wt%)200 mlに1週間冷浸し、ろ別
して得らnlこ抽出液のエタノールを留去し、精製水を
加えて抽出液のエタノール含有量が50wt%になるよ
うに調整し、更にこれを7〜10週間冷所で熟成しfコ
後、ろ別して100 mlの朝鮮ニンジンエキスを得1
こ。50 y of crushed Panax carrots were cold soaked in 200 ml of aqueous ethanol (90 wt% ethanol) for 1 week, filtered, and the ethanol of the resulting extract was distilled off, and purified water was added to make the ethanol content of the extract 50 wt%. This was further aged in a cold place for 7 to 10 weeks, and then filtered to obtain 100 ml of Korean carrot extract.
child.
前記特定の血行促進剤あるいは細胞賦活剤を本発明の化
粧料に配合する量は、その作用効果あるいは当該化粧料
の剤型等により適宜調整されるものであるが通常後記の
第1表に示す配合量が好適である。なお配合量は化粧料
組成物の全社重斌を基準とし1こ。The amount of the specific blood circulation promoter or cell activator to be blended into the cosmetic of the present invention is adjusted as appropriate depending on its effect or the dosage form of the cosmetic, but is usually shown in Table 1 below. The blending amount is suitable. The amount of compounding is 1 part based on the company's cosmetic composition.
第 1 表
本発明の皮膚老化防止用化粧料は、前記特定の!
脂環式化合物と、前記特定の血行促進剤あるいは細胞賦
活剤とを、クリーム、乳液、ローション等の皮膚化粧料
基剤の中に直接添加するか、またはそれらの化合物を油
相成分、水相成分、アルコール等の溶剤に溶解して配合
し、乳化、混合、分散、溶解、可溶化等の処理を行なう
ことによって調製される。Table 1 The cosmetics for preventing skin aging of the present invention are as specified above!
The alicyclic compound and the specific blood circulation promoter or cell activator may be directly added to a skin cosmetic base such as a cream, emulsion, or lotion, or these compounds may be added to an oil phase component or an aqueous phase component. It is prepared by dissolving and blending ingredients in a solvent such as alcohol, and performing treatments such as emulsification, mixing, dispersion, dissolution, and solubilization.
(発明の効果)
本発明の皮膚老化防止用化粧料は、米和泊増−1tR−
−JRt=瑠f#埠皮膚機能を冗進し、肌のしわを防止
し、肌理(きめ)こまかなかつしっとりとしTこ皮膚に
すると共に、優れた皮膚老化防止効果(荒れ肌改善効果
、角質改善効果に優れ、ターンオーバー速度を早める効
果)を、相乗的にかつ短時間に発現し、持続する等、顕
著な効果を奏し得る。(Effect of the invention) The cosmetic for preventing skin aging of the present invention is
- JRt = Ruf # Bu Enhances skin function, prevents skin wrinkles, makes skin smooth and moisturized, and has excellent skin aging prevention effects (improving rough skin, improving keratin) It can produce remarkable effects, such as synergistically developing and sustaining the effect of increasing the turnover rate and speeding up the turnover rate.
(実施例) 以下、実施例について説明する。(Example) Examples will be described below.
なお、実施例に示す%とは重歓%を意味する。Note that % shown in Examples means % of weight.
実施例に記載の角質層のターンオーバー速度測定方法、
荒n肌改善効果の測定試験法、角質改善効果の測定試験
法は下記の通りである。Method for measuring turnover rate of stratum corneum described in Examples,
The test method for measuring the rough skin improvement effect and the measurement test method for the keratin improvement effect are as follows.
(1)角質層のターンオーバー速度測定方法蛍光色素の
タンジルクロライドを白色ワセリン=7−
中に5重量%配合し1こ軟膏を作り、被検者の前腕部の
皮膚に24時間閉塞貼布し、角質層にダンジルクロライ
ドを浸透結合させる。その後同じ部位に1日2回(朝・
夕)被検試料を塗布し、毎日ダンジルクロライドの蛍光
をしらべ、その蛍光が消滅するまでの日数を皮膚角質層
のターンオーバー速度とし1こ。なお、通常の皮膚角質
層のターンオーバー速度は14〜16日であるが、老化
し1こ皮膚においては18日前後にのびる。それに対し
て老化防止効果が現れると12日前後にまで短縮される
。(1) Method for measuring turnover rate of stratum corneum Mix 5% by weight of tanzyl chloride, a fluorescent dye, in white vaseline = 7- to make one ointment, and apply it to the skin of the subject's forearm for 24 hours as an occlusive patch. and allows danzyl chloride to penetrate and bind to the stratum corneum. After that, apply to the same area twice a day (morning and
Evening) Apply the test sample, check the fluorescence of danzyl chloride every day, and count the number of days until the fluorescence disappears as the turnover rate of the skin's stratum corneum. Note that the normal turnover rate of the stratum corneum of the skin is 14 to 16 days, but in aged skin, the turnover rate increases to around 18 days. On the other hand, if the anti-aging effect appears, the time will be shortened to around 12 days.
(2)荒れ肌改善効果の測定試験法
下脚に荒れ肌を有する中高年被験者20名を対塗布し、
試験開始前および終了後の皮膚の状態を第2表の基準に
より判定しTコ。右側下脚は試料を塗布せず対照とし1
こ。(2) Test method for measuring the effect of improving rough skin.
The condition of the skin before and after the test was evaluated according to the criteria in Table 2. No sample was applied to the right lower leg as a control.
child.
第2表 皮膚乾燥度の判定基準
−:正常
± :軽微乾燥、落屑なし
十 二乾燥、落屑軽度
++:乾燥、落屑中等度
十+十:乾燥、落屑顕著
試験前後の試験部位と対照部位の判定結果を比較し、皮
膚乾燥度が2段階以上改善された場合(例えば+−一、
十+→±)を「有効」、1段階改善されy、=場合を「
やや有効」、変化がなかった場合を「無効」としfコ。Table 2 Judgment criteria for skin dryness -: Normal ±: Slight dryness, no flaking 12 Dryness, mild flaking ++: Moderate dryness, flaking 10+10: Dryness, marked desquamation Judgment of test and control areas before and after the test Compare the results and if the skin dryness has improved by two or more levels (e.g. +-1,
10 + → ±) is "valid", 1 step improved y, = case is "
If there is no change, it is considered ``slightly effective'', and if there is no change, it is ``invalid''.
尚、試験期間中に皮膚の乾燥が進んだ例はなかっTコ。Additionally, there were no cases of skin dryness during the test period.
(3)角質改善(角質細胞の抗剥離性増大)効果の測定
試験法
前述の荒れ肌改善測定試験開始前および終了後の被験部
皮膚にスコッチテープにチバンメンディングテーブ)を
接着し、これを剥離し1こ時テープに付着し1こ角質細
胞の状態全走査型電子顕微鏡によって詳細に調べ、第3
表の基準によって皮膚角質細胞抗剥離性ケ分離【7、角
質改善効果を求め1こ。(3) Test method for measuring the effect of improving keratin (increasing the anti-peeling properties of keratinocytes) A scotch tape (Tiban mending tape) is adhered to the test area skin before and after the above-mentioned rough skin improvement measurement test, and this is peeled off. The condition of the keratinocytes attached to the tape was examined in detail using a full-scanning electron microscope.
According to the criteria in the table, the skin keratin cell anti-exfoliation property is separated [7], and the keratin improving effect is determined.
第3表
角質教養効果(角質細胞抗剥離性増大)の判定基準
評価点lニスケールを認めず
# 2:小スケール点在
l 3:小〜中スケール顕著
# 4:大スケール顕著
第3表は4週間連続塗布後の試験部位の評価点と対照部
位のそれとの差が2点以上の場合を「有効」、1点の場
合を「やや有効」、0点の場合を「無効」としγこ。Table 3 Judgment criteria for keratin education effect (increased anti-desquamation property of keratinocytes) Evaluation points 1 Two scales not recognized # 2: Small scale scattered 1 3: Small to medium scale noticeable # 4: Large scale noticeable Table 3 is 4 If the difference between the evaluation score of the test site and that of the control site after weekly continuous application is 2 points or more, it is considered "effective", if it is 1 point, it is "slightly effective", and if it is 0 points, it is "invalid".
尚、試験部位の評価点が対照部位のそれよりも第4表
上記第3表に示す処方の各スキンミルクを前記の方法に
より調製しtこ。得られfコ実施例1および比較例3の
各スキンクリームの皮膚老化防止効果(荒れ肌改善効果
、角質改善効果、角質層のターンオーバー速度)の試験
結果普ζついては第5表〜第7表ζこ、比較例1および
比較例2の皮膚老化防止効果の試験結果については第8
表に示した。In addition, each skin milk with the formulation shown in Table 3 above in Table 4 was prepared by the above-mentioned method and the evaluation score of the test site was higher than that of the control site. Test results of skin anti-aging effects (improving effect on rough skin, improving effect on dead skin cells, turnover rate of stratum corneum) of each skin cream of Example 1 and Comparative Example 3 are shown in Tables 5 to 7. Regarding the test results of the skin aging prevention effect of Comparative Example 1 and Comparative Example 2, see Part 8.
Shown in the table.
第5表:前記脂環式化合物の1を配合し1こスキンミル
クの皮膚老化防止効果
第6表:前記脂環式化合物の2を配合し1こスキンミル
クの皮膚老化防止効果
第7表;前記脂環式化合物の3を配合し1こスキンミル
クの皮膚老化防止効果
第8表:前記脂環式化合物を配合しないスキンミルクの
皮膚老化防止効果
第5表〜第8表の結11t!力)ら明らかなように、前
□記特定の脂環式化合物(前記脂環式化合物の1
〜3)と、前記の血行促進剤あるいは細胞賦活剤エラス
チン、水溶性コラーゲン、センブリエキス、ω」鮮ニン
ジンエキス)とを併用配合し1こ本発明のスキンミルク
(実施例1−1〜実施例1−24)では皮膚老化防止効
果(荒れ肌改善効果、角質改善効果および角質層のター
ンオーバー速度を5速くする効果)が、相乗的に向上し
、発現している。Table 5: Skin anti-aging effects of one skin milk containing one of the alicyclic compounds 1 Table 6: Skin anti-aging effects of one skin milk containing one of the alicyclic compounds 2 Table 7; Table 8: Anti-aging effect on the skin of skin milk containing one of the alicyclic compounds 3: Preventing skin aging effect of skin milk containing no alicyclic compound Table 5 to Table 8 Summary 11t! As is clear from the above □ specific alicyclic compound
~3) and the aforementioned blood circulation promoter or cell activator elastin, water-soluble collagen, Oriental japonica extract, ω'' fresh carrot extract) and the skin milk of the present invention (Example 1-1 to Example 1). 1-24), the skin aging prevention effects (improving rough skin, improving keratin, and increasing the turnover rate of the stratum corneum by 5%) are synergistically improved and expressed.
これに対して、前記特定の脂環式化合物のみを配合しf
コ比較例3(比較例3−1〜比較例3−3)のスキンミ
ルクおよび前記の血行促進剤あるいは細胞賦活剤のみを
配合し1こ比較例2のスキンミルク(比較例2−1〜比
較例2−8)では、皮膚老化防止効果が低い。そして、
前記特定の脂環式化合物と、前記の血行促進剤あるいは
細胞賦活剤の両者を含有(併用)しない比較例1のスキ
ンミルク(スキンミルクベース)では皮膚老化防止効果
は認めらnない。On the other hand, if only the specific alicyclic compound is blended, f
The skin milk of Comparative Example 3 (Comparative Examples 3-1 to 3-3) and the above-mentioned blood circulation promoter or cell activator were blended together. In Example 2-8), the effect of preventing skin aging is low. and,
The skin milk (skin milk base) of Comparative Example 1 that does not contain (combined) both the specific alicyclic compound and the blood circulation promoter or cell activator has no skin aging prevention effect.
次に、前記の各スキンミルクを小じわの悩みを有する被
検者(25才〜45才の女性)50人に1日2回(朝、
夕)連続:3ケ月間塗布便用せ1ノめ、1ケ月後および
3ケ月後の結果(実用テストの結果)を第9表〜第16
表に示しT、=。Next, each of the skin milks mentioned above was given to 50 subjects (women aged 25 to 45) who had problems with fine lines twice a day (in the morning,
Evening) Continuous: Apply the application for 3 months, and the results (practical test results) after 1 month and 3 months are shown in Tables 9 to 16.
The table shows T,=.
第9表:前記脂環式化合物の1を配合し1こスキンミル
クの実用テストの結果(1
ケ月後)
第10表二前記脂環式化合物の1を配合し1こスキンミ
ルクの実用テストの結果
(3ケ月後)
第11表:前記脂環式化合物の2を配合し1こスキンミ
ルクの実用テストの結果
(1″r月後)
第12表:前il[l!脂環式化合物の2を配合し1こ
スキンミルクの来月テストの結果
(3ケ月後)
第13表:前記脂環式化合物の3を配合し1こスキンミ
ルクの実用テストの結果
(1ケ月後)
第14表:前記脂環式化合物の3を配合し1こスキンミ
ルクの実用テストの結果
(3ケ月後)
〜+l
第15表二前記の脂環式化合物を配合しないスキンミル
クの実相テストの結果
(1ケ月後)
第16表:前記の脂環式化合物を配合しないスキンミル
クの実用テストの結果
(3ケ月後)
併用配合しTこ本発明のスキンクリーム(実施例1−1
〜実施例1〜24)では、しわをのばす効果、きめに対
する効果、しっとり感に対する効果のいずれもが、使用
し始めて1ケ月後力)ら現わΩて、速効性が顕著で、か
つ持続性を有し、シ〃)も諸効果が著しく優nている。Table 9: Practical test results of 1 skin milk containing 1 of the above alicyclic compound (after 1 month) Table 10: Results of practical test of 1 skin milk containing 1 of the above alicyclic compound Results (after 3 months) Table 11: Practical test results of skin milk containing 2 of the above alicyclic compounds (after 1 month) Table 12: Previous il[l! Results of next month's test of 1 skin milk containing 2 (after 3 months) Table 13: Practical test results of 1 skin milk containing 3 of the above alicyclic compound (after 1 month) Table 14 :Results of a practical test of skin milk containing 3 of the above alicyclic compounds (after 3 months) ~ +l Table 15 2 Results of a practical test of skin milk containing no alicyclic compounds mentioned above (after 1 month) Table 16: Practical test results of the skin milk without the alicyclic compound (after 3 months) Skin cream of the present invention (Example 1-1)
In Examples 1 to 24), the effects of smoothing out wrinkles, improving texture, and improving moisturizing sensation were all visible after one month of use, with remarkable rapid effects and long-lasting effects. The effects of C) are also significantly superior.
こnに対して、前記特定の脂環式化合物のみを配合しT
コ比較例3(比較例3−1〜比較例3−3)および前記
の血行促進剤あるいは細胞賦活剤のみを配合しTコ比較
例2(比較例2−1〜比較例2−8)のスキンミルクで
はいずnの効果においても比較的低くかつ遅効性である
。なお、対照品としてのスキンミルクベース(基剤)で
は、前記の効果が認められなかっ1こ。In contrast, when only the specific alicyclic compound is blended,
Comparative Example 3 (Comparative Examples 3-1 to 3-3) and Comparative Example 2 (Comparative Examples 2-1 to 2-8) containing only the blood circulation promoter or cell activator. Skin milk has relatively low and slow-acting effects. In addition, the above-mentioned effect was not observed with skin milk base (base) as a control product.
Claims (1)
3,3,0〕オクタン−3−オン、6−(5−エトキシ
ヘプト−1−イル)−ビシクロ−〔3,3,0〕オクタ
ン−3−オン、6−(5−ヒドロキシヘプト−1−イル
)−ビシクロ−〔3,3,0〕オクタン−3−オンから
なる群から選択された脂環式化合物の少なくとも一つと
、γ−アミノ酪酸、ビタミンEオロテート、ジイソプロ
ピルアミンジクロロアセテート、ヒアルロン酸、エラス
チン、水溶性コラーゲン、センブリエキス、朝鮮ニンジ
ンエキスからなる群から選択された物質の少なくとも一
つとを配合してなる皮膚老化防止用化粧料。[Claims] 6-(5-methoxyhept-1-yl)-bicyclo-[
3,3,0]octan-3-one, 6-(5-ethoxyhept-1-yl)-bicyclo-[3,3,0]octan-3-one, 6-(5-hydroxyhept-1-yl) yl)-bicyclo-[3,3,0]octan-3-one, and at least one alicyclic compound selected from the group consisting of γ-aminobutyric acid, vitamin E orotate, diisopropylamine dichloroacetate, hyaluronic acid, A cosmetic for preventing skin aging, which is formulated with at least one substance selected from the group consisting of elastin, water-soluble collagen, Jasmine japonica extract, and Korean ginseng extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59178971A JPS6156114A (en) | 1984-08-27 | 1984-08-27 | Cosmetic for preventing skin aging |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59178971A JPS6156114A (en) | 1984-08-27 | 1984-08-27 | Cosmetic for preventing skin aging |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6156114A true JPS6156114A (en) | 1986-03-20 |
JPS6220165B2 JPS6220165B2 (en) | 1987-05-06 |
Family
ID=16057859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59178971A Granted JPS6156114A (en) | 1984-08-27 | 1984-08-27 | Cosmetic for preventing skin aging |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6156114A (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07242530A (en) * | 1994-03-03 | 1995-09-19 | Kanebo Ltd | Skin cosmetic |
FR2717389A1 (en) * | 1994-03-18 | 1995-09-22 | Lvmh Rech | Use of ginsenoside Ro or a plant extract containing it to stimulate collagen synthesis. |
JPH0967262A (en) * | 1995-08-31 | 1997-03-11 | Shiseido Co Ltd | Skin activator and skin activating food |
US5767106A (en) * | 1992-02-21 | 1998-06-16 | Hyal Pharmaceutical Corporation | Treatment of disease and conditions associated with macrophage infiltration |
US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5962433A (en) * | 1990-09-18 | 1999-10-05 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5977088A (en) * | 1991-07-03 | 1999-11-02 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US5990096A (en) * | 1990-09-18 | 1999-11-23 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US6140312A (en) * | 1992-02-20 | 2000-10-31 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US6218373B1 (en) | 1992-02-20 | 2001-04-17 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
JP2012211130A (en) * | 2011-03-23 | 2012-11-01 | Daiichi Sankyo Healthcare Co Ltd | IN VIVO MAILLARD REACTION INHIBITOR OR AGEs GENERATION INHIBITOR |
JP2020514739A (en) * | 2017-03-06 | 2020-05-21 | ハプルサイエンス・インコーポレイテッド | Composition for measuring, preventing or improving skin aging using HAPLN1 |
JP2021075539A (en) * | 2021-01-22 | 2021-05-20 | ハプルサイエンス・インコーポレイテッド | Composition for measuring or preventing or improving skin aging using hapln1 |
-
1984
- 1984-08-27 JP JP59178971A patent/JPS6156114A/en active Granted
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990096A (en) * | 1990-09-18 | 1999-11-23 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5962433A (en) * | 1990-09-18 | 1999-10-05 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5977088A (en) * | 1991-07-03 | 1999-11-02 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US6218373B1 (en) | 1992-02-20 | 2001-04-17 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US6140312A (en) * | 1992-02-20 | 2000-10-31 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US5767106A (en) * | 1992-02-21 | 1998-06-16 | Hyal Pharmaceutical Corporation | Treatment of disease and conditions associated with macrophage infiltration |
JPH07242530A (en) * | 1994-03-03 | 1995-09-19 | Kanebo Ltd | Skin cosmetic |
US5747538A (en) * | 1994-03-18 | 1998-05-05 | L.V.M.H. Recherche | Use of ginsenoside R0 or a plant extract containing same to promote collagen synthesis |
WO1995025524A1 (en) * | 1994-03-18 | 1995-09-28 | Lvmh Recherche | USE OF GINSENOSIDE Ro OR A PLANT EXTRACT CONTAINING SAME TO PROMOTE COLLAGEN SYNTHESIS |
FR2717389A1 (en) * | 1994-03-18 | 1995-09-22 | Lvmh Rech | Use of ginsenoside Ro or a plant extract containing it to stimulate collagen synthesis. |
JPH0967262A (en) * | 1995-08-31 | 1997-03-11 | Shiseido Co Ltd | Skin activator and skin activating food |
JP2012211130A (en) * | 2011-03-23 | 2012-11-01 | Daiichi Sankyo Healthcare Co Ltd | IN VIVO MAILLARD REACTION INHIBITOR OR AGEs GENERATION INHIBITOR |
JP2016130265A (en) * | 2011-03-23 | 2016-07-21 | 第一三共ヘルスケア株式会社 | Agent for inhibiting maillard reaction in living body or ages production inhibitor |
JP2020514739A (en) * | 2017-03-06 | 2020-05-21 | ハプルサイエンス・インコーポレイテッド | Composition for measuring, preventing or improving skin aging using HAPLN1 |
JP2021075539A (en) * | 2021-01-22 | 2021-05-20 | ハプルサイエンス・インコーポレイテッド | Composition for measuring or preventing or improving skin aging using hapln1 |
Also Published As
Publication number | Publication date |
---|---|
JPS6220165B2 (en) | 1987-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111700853B (en) | Cosmetic composition with anti-allergy repairing effect and application thereof | |
CN106309154A (en) | Skin care substrate with long acting moisturizing and whitening effects and preparation and application of skin care substrate | |
JPS6156114A (en) | Cosmetic for preventing skin aging | |
CN110974767A (en) | Composition for skin barrier regeneration repair and application thereof | |
US6193975B1 (en) | Use of potentilla erecta extract in the cosmetic and pharmaceutical field | |
CN112716814A (en) | Double-layer shaking essence and preparation method thereof | |
CN110302091B (en) | Composition containing nicotinamide adenine dinucleotide for resisting skin aging and preparation method and application thereof | |
JP3159419B2 (en) | Cosmetics | |
JP2004123563A (en) | Cosmetic containing fruit oil obtained from hippophae and ingredients extracted from other galenicals | |
CN110151581B (en) | Whitening composition containing glabridin and nanoemulsion preparation thereof | |
JPH0776513A (en) | Cosmetic for preventing skin aging | |
CN111700849A (en) | Whitening composition, cosmetic and application | |
JPS62138411A (en) | Cosmetic for preventing skin from ageing | |
SK34794A3 (en) | Skin regenerating compositions | |
JPS60116618A (en) | Cosmetic | |
JP3170700B2 (en) | Cosmetic for preventing skin aging | |
JPS60184005A (en) | Cosmetic for preventing aging of skin | |
JPH0436221A (en) | Hair tonic | |
JPH11335226A (en) | Skin lotion | |
JP2000109417A (en) | Cosmetic for improving somber color | |
CN109431880B (en) | Whitening repairing agent and preparation method of sleeping mask with whitening repairing function | |
CN113274339A (en) | Silicone oil cream with itching relieving and moisture keeping effects and preparation method thereof | |
JPH04334308A (en) | Skin cosmetic | |
JPS62148414A (en) | Skin cosmetic | |
JP3101090B2 (en) | External preparation for skin |